{"id":"W4310554573","doi":"10.1016/s1470-2045(22)00687-8","title":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":104,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche; Roche","keywords":"Medicine; Vemurafenib; Atezolizumab; Interim analysis; Placebo; Internal medicine; Tolerability; Oncology; Adverse effect; Surgery; Randomized controlled trial; Metastatic melanoma; Pembrolizumab; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004105033,0.00209261,0.00404095,0.0004045912,0.0003740909,0.00184462,0.001175625,0.001756868,0.00327141],"category_scores_gemma":[0.001633149,0.0007734328,0.005019004,0.0003799086,0.0009149283,0.001640413,0.0006503087,0.004613081,0.0009403778],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001532682,"about_ca_system_score_gemma":0.001392166,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001220742,"about_ca_topic_score_gemma":0.003152925,"domain_scores_codex":[0.9989215,0.000483428,0.00004117809,0.0001826902,0.00008228022,0.000288897],"domain_scores_gemma":[0.9988275,0.0002424135,0.000230533,0.0001402853,0.00007099923,0.0004882646],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9626947,0.003310014,0.002225103,0.0003431217,0.002375417,0.00004865911,0.00006073816,0.001620312,0.004110823,0.00009046809,0.001917178,0.02120343],"study_design_scores_gemma":[0.7764504,0.1941612,0.02168575,0.0000600119,0.002980487,0.0001590678,0.00005256892,0.001189964,0.001351712,0.0002824996,0.001570195,0.00005606729],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914148,0.003169445,0.0005311716,0.0006538085,0.0002893747,0.0004904216,0.002029243,0.00009760702,0.001324174],"genre_scores_gemma":[0.9872522,0.001529428,0.0009812092,0.001088843,0.0002569174,0.0009666019,0.004953414,0.00005839521,0.002912966],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004105033,"threshold_uncertainty_score":0.02170974,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01725053882236342,"score_gpt":0.2996574736859282,"score_spread":0.2824069348635648,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}